News - RET fusion - LARVOL VERI

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations (clinicaltrials.gov)

P1/2, N=12, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting

6 days ago

Enrollment closed

ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

RET fusion • ALK fusion • ROS1 fusion

VENTANA ALK (D5F3) CDx Assay

Rybrevant (amivantamab-vmjw)

12d

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov)

P2, N=32, Not yet recruiting, University of Washington

12 days ago

New P2 trial • Checkpoint inhibition

ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CXCL8 (Chemokine (C-X-C motif) ligand 8)

RET fusion • ALK fusion • ROS1 fusion

SX-682 • Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)

13d

THE INFLUENCE OF AGE-INDEPENDENT SOMATIC DRIVER ALTERATIONS ON CLINICAL OUTCOMES IN PEDIATRIC AND YOUNG ADULT THYROID CANCER. (PubMed, Eur Thyroid J)

While prognosis steadily improved with age, mutation status remained the dominant factor determining outcomes. Somatic drivers offer prognostic insights independent of age in paediatric and young adult DTC, establishing a molecular framework for precision risk stratification that complements traditional clinical staging and age-based assessments.

13 days ago

Clinical data • Journal

BRAF (B-raf proto-oncogene) • RET (Ret Proto-Oncogene) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • RAS (Rat Sarcoma Virus) • DICER1 (Dicer 1 Ribonuclease III)

BRAF V600E • BRAF V600 • RET fusion • RAS mutation

15d

CTONG 2508: Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung) (clinicaltrials.gov)

P2, N=115, Recruiting, Guangdong Association of Clinical Trials | Not yet recruiting --> Recruiting

15 days ago

Enrollment open

ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

RET fusion • ALK fusion • ROS1 fusion

Tyvyt (sintilimab)

16d

Selpercatinib-induced renal tubular damage resulting in symptomatic hyponatremia and polyuria: a case report. (PubMed, Cancer Chemother Pharmacol)

Our report indicates an association between selpercatinib plasma concentration and renal tubular damage, and emphasizes the importance of recognizing selpercatinib-induced tubular injury. This report also provides guidance for the management of these renal manifestations and for rechallenge guided by TDM, highlighting a potential role for TDM in dose determinations after selpercatinib-induced renal toxicity.

16 days ago

Journal

RET (Ret Proto-Oncogene)

RET fusion • RET mutation • RET positive

Retevmo (selpercatinib)

19d

Tumor Lysis Syndrome Induced by Selpercatinib in Rearranged During Transfection (RET) Fusion-Positive Non-Small-Cell Lung Cancer. (PubMed, Cureus)

Selpercatinib was discontinued, and treatment with intravenous hydration, febuxostat, and furosemide was initiated. This case highlights that potent targeted therapy can trigger TLS even in the absence of conventional risk factors. Early recognition and aggressive management are essential to mitigate risk and allow continuation of effective treatment.

19 days ago

Journal

RET (Ret Proto-Oncogene) • KIF5B (Kinesin Family Member 5B)

RET fusion • RET positive

Retevmo (selpercatinib)

21d

LIBRETTO-432: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)

P3, N=152, Active, not recruiting, Eli Lilly and Company | Trial primary completion date: Jan 2026 --> May 2026

21 days ago

Trial primary completion date

RET (Ret Proto-Oncogene)

RET fusion

Retevmo (selpercatinib)

26d

Optimizing communication for ultrafast lung cancer biomarker testing: the UTOPIA pilot study. (PubMed, Lung Cancer)

An ultrafast biomarker testing workflow for lung cancer, enabled by MTB-driven triage and structured team communication, can reliably generate comprehensive molecular reports within 72 h. This approach may reduce TAT-related treatment delays and support timely biomarker-guided therapy for patients with NSCLC.

26 days ago

Journal • Biomarker testings

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene)

BRAF V600E • KRAS G12C • BRAF V600 • RET fusion • MET exon 14 mutation • ALK fusion • RET mutation • KRAS G12

26d

Cerebrospinal fluid ctDNA clarifies clonal divergence: leptomeningeal flare of EGFR-mutant disease after switch to selpercatinib for acquired RET fusion. (PubMed, J Liq Biopsy)

A 67-year-old woman with EGFR exon 19-deleted adenocarcinoma received afatinib followed by long-term osimertinib. CSF liquid biopsy provided actionable, compartment-specific genotyping that outperformed cytology and guided effective retreatment. Incorporating CSF ctDNA into routine evaluation may improve therapeutic alignment across sanctuary sites; when feasible, maintaining EGFR blockade should be considered when CNS involvement is suspected in EGFR-mutated NSCLC in routine practice.

26 days ago

Journal • Circulating tumor DNA

EGFR (Epidermal growth factor receptor) • RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6)

EGFR mutation • EGFR exon 19 deletion • RET fusion • CCDC6-RET fusion

Tagrisso (osimertinib) • Gilotrif (afatinib) • Retevmo (selpercatinib)

29d

Low-order assemblies drive oncogenic RTK fusion signaling without condensation. (PubMed, bioRxiv)

A panel of various other cancer-driving RTK fusions showed that low-order multimerization was universal across fusions, whereas mesoscale condensation was rare and did not correlate with signaling. Our results suggest that low-order fusion multimerization is sufficient to drive its phosphorylation, which is necessary and sufficient to trigger downstream oncogenic signaling.

29 days ago

Journal

ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • EML4 (EMAP Like 4)

RET fusion • ALK fusion

29d

Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC - Insights From Genomics, Proteomics, and Metabolomics. (PubMed, Lung Cancer (Auckl))

Although promising, most biomarkers require prospective validation in large, uniformly treated cohorts. Integrative strategies-particularly when combined with AI-driven analytics-hold potential to refine patient stratification and guide clinical use of ICIs in NSCLC.

29 days ago

Review • Journal • Checkpoint inhibition • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Metabolomic study

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • FASLG (Fas ligand) • S100A8 (S100 Calcium Binding Protein A8) • SAA1 (Serum Amyloid A1) • CASP8 (Caspase 8)

TP53 mutation • BRAF V600E • KRAS mutation • BRAF V600 • RET fusion • STK11 mutation • TMB-L • KEAP1 mutation • ROS1 fusion